Although funds raised for med-tech companies in the third quarter were less than half of the amount raised in the second quarter and 14% less than the first quarter, it was still the best quarter of 2020 for IPOs and venture capital (VC) financings. It also pushed the money raised through all financing types to its highest level in four years.
According to BioWorld, almost $85 billion was raised by public and private biopharma companies globally in the second and third quarters alone, bringing the dollars generated to date to more than $100 billion – a total that smashes the existing record of about $69 billion that was raised in 2015.